BRPI0508082A8 - Anticorpo monoclonal de tenascina antihumano - Google Patents

Anticorpo monoclonal de tenascina antihumano

Info

Publication number
BRPI0508082A8
BRPI0508082A8 BRPI0508082A BRPI0508082A BRPI0508082A8 BR PI0508082 A8 BRPI0508082 A8 BR PI0508082A8 BR PI0508082 A BRPI0508082 A BR PI0508082A BR PI0508082 A BRPI0508082 A BR PI0508082A BR PI0508082 A8 BRPI0508082 A8 BR PI0508082A8
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
antihuman
tenascin
tenascin monoclonal
seq
Prior art date
Application number
BRPI0508082A
Other languages
English (en)
Inventor
De Santis Rita
Pelliccia Angela
Palombo Giovanna
Carminati Paolo
Original Assignee
Tecnogen Scpa
Tecnogen Spa
Sigma Tau Ind Farmaceuti
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen Scpa, Tecnogen Spa, Sigma Tau Ind Farmaceuti, Alfasigma Spa filed Critical Tecnogen Scpa
Publication of BRPI0508082A publication Critical patent/BRPI0508082A/pt
Publication of BRPI0508082A8 publication Critical patent/BRPI0508082A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO MONOCLONAL DE TENASCINA ANTIHUMANO. Um anticorpo monoclonal de tenascina antihumano é descrito, cujas seqüências de regiões variáveis das cadeias leve e pesada são a SEQ ID NO: 1 e a SEQ ID NO: 2, respectivamente, seus fragmentos proteolíticos capazes de se ligar a um epitopo antigênico dentro da região A(1-4)-D da tenascina humana, seus derivados recombinantes, seus conjugados e seus análogos funcionais similares capazes de se ligar a um epitopo antigênico dentro da região A(1-4)-D da tenascina humana.
BRPI0508082A 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina antihumano BRPI0508082A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody

Publications (2)

Publication Number Publication Date
BRPI0508082A BRPI0508082A (pt) 2007-07-17
BRPI0508082A8 true BRPI0508082A8 (pt) 2017-12-26

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508082A BRPI0508082A8 (pt) 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina antihumano

Country Status (15)

Country Link
US (1) US7989171B2 (pt)
EP (1) EP1718678B1 (pt)
JP (1) JP5191036B2 (pt)
KR (1) KR101266389B1 (pt)
CN (1) CN1946740B (pt)
AR (1) AR047819A1 (pt)
AU (1) AU2005217237B2 (pt)
BR (1) BRPI0508082A8 (pt)
CA (1) CA2558718C (pt)
ES (1) ES2654065T3 (pt)
IT (1) ITRM20040105A1 (pt)
MX (1) MXPA06009674A (pt)
PL (1) PL1718678T3 (pt)
PT (1) PT1718678T (pt)
WO (1) WO2005082938A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
EP2999967B1 (en) * 2013-05-21 2020-05-20 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
MXPA01011230A (es) * 1999-05-01 2002-10-04 Univ New Jersey Med Crecimiento exterior de neurita y guia por tenascina-c.
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ES2352180T3 (es) * 2002-02-26 2011-02-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anticuerpo monoclonal de anti-tenascina humana.
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
EP1718678A2 (en) 2006-11-08
MXPA06009674A (es) 2007-03-21
JP2008506355A (ja) 2008-03-06
CN1946740A (zh) 2007-04-11
JP5191036B2 (ja) 2013-04-24
PL1718678T3 (pl) 2018-05-30
US20100297003A1 (en) 2010-11-25
AU2005217237B2 (en) 2011-12-22
KR20070002029A (ko) 2007-01-04
WO2005082938A2 (en) 2005-09-09
US7989171B2 (en) 2011-08-02
EP1718678B1 (en) 2017-10-11
CN1946740B (zh) 2012-09-05
AU2005217237A1 (en) 2005-09-09
ITRM20040105A1 (it) 2004-05-27
CA2558718C (en) 2015-01-13
BRPI0508082A (pt) 2007-07-17
PT1718678T (pt) 2017-12-29
AR047819A1 (es) 2006-02-22
ES2654065T3 (es) 2018-02-12
WO2005082938A3 (en) 2005-12-15
KR101266389B1 (ko) 2013-05-28
CA2558718A1 (en) 2005-09-09
HK1100848A1 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
EP1198250B8 (en) Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CY1106594T1 (el) Αντισωματα εναντι ανθρωπινης il-12
NZ568769A (en) Human monoclonal antibodies against CD20
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
HRP20090517T1 (hr) Protutijela na interleukin-10
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
PE20130643A1 (es) Conjugados de anticuerpos multifuncionales
CO6230996A2 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
CR8231A (es) Anticuerpos rg1 y uso de los mismos
PE20050727A1 (es) Anticuerpos dirigidos a c-met
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
DE60043784D1 (de) Serpentinetransmembranrezeptoren exprimiert in menschlichem prostatakrebs und ihre verwendungen
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
BRPI0508082A (pt) anticorpo monoclonal de tenascina antihumano
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DK1173766T3 (da) Isoform af tenascin-C som markör for neoplasier
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
ATE361761T1 (de) Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
AR013735A1 (es) Inmunoensayo para el propeptido del procolageno iii c terminal, anticuerpos , propeptido del procolageno iii c terminal y uso de los anticuerpos.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TECNOGEN S.P.A. (IT)

Free format text: ALTERADO DE: TECNOGEN S.C.P.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2553 DE 10/12/2019.